BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-5041 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-5041\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06568094-11086@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HRS-5041: Phase 1/2 readout est. (NCT06568094)
DESCRIPTION:HRS-5041\, phase 1/2\, Prostate Cancer.\nStudy: A Study of HRS-
 5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Pro
 state Cancer\nEstimated primary completion: December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/hrs-5041#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06568094
URL:https://assetmemo.bio/drug/hrs-5041#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06830850-11086@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HRS-5041: Phase 1 readout est. (NCT06830850)
DESCRIPTION:HRS-5041\, phase 1\, Prostate Cancer.\nStudy: A Trial of HRS-50
 41-103 to Evaluate the Safety\, Tolerability\, Pharmacokinetics and Effica
 cy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate C
 ancer\nEstimated primary completion: 30 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/hrs-5041#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06830850
URL:https://assetmemo.bio/drug/hrs-5041#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06738745-11086@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:HRS-5041: Phase 2 readout est. (NCT06738745)
DESCRIPTION:HRS-5041\, phase 2\, Prostate Cancer.\nStudy: Study of HRS-2189
  Combined HRS-5041 in Prostate Cancer\nEstimated primary completion: 31 Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5041#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0673
 8745
URL:https://assetmemo.bio/drug/hrs-5041#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407283-11086@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:HRS-5041: Phase 1/2 readout est. (NCT07407283)
DESCRIPTION:HRS-5041\, phase 1/2\, Prostate Cancer.\nStudy: A Clinical Stud
 y of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer\nE
 stimated primary completion: November 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/hrs-5041#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07407283
URL:https://assetmemo.bio/drug/hrs-5041#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115446-11086@assetmemo.bio
DTSTAMP:20261121T005702Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-5041: Phase 1 readout est. (NCT07115446)
DESCRIPTION:HRS-5041\, phase 1\, Prostate Cancer.\nStudy: Phase Ib Study of
  HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer\nEstimated pr
 imary completion: December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/hrs-5041#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07115446
URL:https://assetmemo.bio/drug/hrs-5041#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
